Tempus AI Stock News

Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than...

Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. “Presenting our latest research is a vital opport...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV a...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference ca...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago's premier integrated academic health system, today announced a collaboration that aims to explore the application of artificial intelligence in clinical care and research. The collaboration, which is expected to span across several disease conditions over time, will s...